1. Introduction {#sec1}
===============

COVID-19 patients with preexisting diseases are at high risk of worse clinical outcomes. There is little data about intensive care COVID-19 patients with different comorbidities and how to deal with them.[@bib1]

2. Case report {#sec2}
==============

A 53-year-old female patient was admitted to the hospital because of fever and cough accompanied with activity chest tightness for 5 days. Her body temperature has been abnormal with the highest point reaching 40 °C, accompanied with chills, fatigue, cough and difficulty in expectoration; no symptoms of gastrointestinal response. The patient was admitted to our hospital because of the medical history of SAA for half a year and the ongoing novel coronavirus epidemic. The patient usually takes cyclosporine for treatment but has not taken it in the last month. She had a history of penicillin and cephalosporin allergy, and medical history of experiencing peripherally inserted central catheter line (removed already).

Physical exam: Her vital signs on arrival at our hospital were body temperature 38.6 °C, blood pressure 139/89 mmHg, respiratory rate 20--30/min, heart rate 110--140/min and SPO2 90%. She appeared pale and weak, and rough breathing sounds in the lungs without marked rales. Labs and imaging: Routine blood tests revealed WBCs 0.28 × 109/L, neutrophils 0.06 × 109/L, lymphocyte 0.21 × 109/L, Hb 56 g/L, PLT 50 × 109/L. Coagulation blood tests revealed PT 15s, APTT 50.1S, Fbg 7.03  g/L, D-Dimer 2.58 μg/ml; PCT 1.44 ng/ml, hs-CRP \>320 mg/L. Biochemical indexes: ALT 11U/L, AST19U/L, ALB 29.1  g/L, TBIL 20.3 μmol/L, creatinine 73 μmol/L, Glu 6.18 mmol/L, LDH 152U/L, hs-cTnT 30.6 pg/ml, CK-MB \<0.1 ng/ml, ferritin 4864.8 μg/L. Cytokines: IL-2R 3002U/L, IL-6544.8 pg/ml, IL-8 1045 pg/ml, IL-10 40.6 pg/ml, TNF-α 16.3 pg/ml. G test \<37.5 pg/ml, GM test 0.06, candida mannan 32.38 pg/ml. Blood culture was methicillin-sensitive staphylococcus aureus. Throat swab virus nucleic acid tests showed negative results for several times (however, IgM-IgG combined antibody test for COVID-19 at day 8 and ten after admission were IgM 34.27AU/ml and 35.20 AU/ml, and IgG 125.01AU/ml and 158.55 AU/ml, indicating positive infection of COVID-19). Chest CT revealed multiple patchy opacities accompanied with multi-sub-pleural nodular shadows.

The patient was subsequently diagnosed with severe pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), accompanied with sepsis and severe aplastic anemia. A combined therapy of Arbidol and Lianhuaqingwen(LH) capsule[@bib2] was considered for etiological antiviral treatment. Initial antibiotic therapy considered imipenem (1g q8h) + vancomycin (1g q12h) + voriconazole (200 mg q12h), combined with immunoglobulin and granulocyte stimulating factor treatment. She felt better after treatment with no abnormities in vital signs; under the condition of oxygen absorption at a concentration of 0.41, SPO2 could reach 99% and inflammatory markers (i.e., CRP, PCT) decreased. Retest of cytokines at day 11 since admission showed IL-2R 1,896U/mL, IL-6 68.33 pg/mL, IL-8458.0 pg/mL, IL-10 7.2 pg/mL, TNF-α 16.2 pg/ml. Imipenem was substituted with cefoperazone/sulbactam (3.0g, q12h) the next day. However, at day 14, the patient developed fever again ranging from 38.5 to 40 °C without hemodynamic changes. Re-examination of chest CT revealed an increased exudation, [Fig. 1](#fig1){ref-type="fig"} , hence antibiotic therapy was treated immediately; blood culture was again conducted. The patient experienced decreased blood pressure, poor consciousness and an increased lactic acid of 4.5 mmol/L at day 18 after admission. Arterial blood gas indicated pH 7.5, PCO2 36, PO2 137, HCO3- 28.1 mmol/L. Retest of cytokines showed IL-6 \>5000.00 pg/mL, PCT 77.60 ng/mL, hs-CRP \>320.0 mg/L, creatinine 126 umol/L. Anti-shock treatment was ineffective, and PO2 dropped to 56 mmHg (15L/min mask oxygen inhalation), and mechanical ventilation was conducted (PC mode, PC 15 cmH2O, PEEP 8 cmH2O, FiO2 100%, VT 431 ml, MPe 10.7L). Blood culture revealed infection of Acinetobacter baumannii, hence treatment strategy was adjusted to tigecycline combined with meropenem, vancomycin, and voriconazole. However, the patient died within 24 h after shock occurred; no significant elevation on WBC, RBC and platelet throughout the entire disease course.Fig. 1Comparison of radiologic manifestations of the patient with severe aplastic anemia complicated with COVID-19. Chest CT scan scheduled on February 23, 2020, showing two nodule-like shadows on the right lung with blurred borders (A), and another shadow on the lower left lung (B). Retest scan scheduled on March 1, 2020, revealing larger nodules on the right lung with significantly increased density (C), and the shadow on the lower left lung was also markedly increased (D).Fig. 1

3. Discussion {#sec3}
=============

In the majority of cases, SAA is an immune-mediated disease with a hematopoietic stem and progenitor cell destruction by an aberrant immune response involving the T cells.[@bib3] ^,^ [@bib4] Blood tests suggested that the patient had trilineage cytopenias with an incredible proportion of lymphocytes and a high level of cytokines, which showed a disorder of immune system caused by SARS-CoV2 infection. The ratio of neutrophil-to-lymphocyte (NLR) should be used with caution when encountering patients with preexisting medical conditions even though there was evidence of association between the ratio and the severity of COVID-19.[@bib1] The patient was ultimately confirmed with SARS-CoV2 infection by positive IgM/IgG test after times of false negative of RT-PCR and atypical radiologic manifestation of chest CT in which no ground-glass opacity was observed, suggesting that cases with occult COVID-19 require particular vigilance and awareness during this pandemic.

To our knowledge, patient with COVID-19 complicated with SSA is quite rare, and this case report reminds us that atypical or even asymptomatic manifestations of COVID-19 may be disguised by inherent diseases. Elevated content of lymphocyte which was considered to favor prognosis of COVID-19, could be a sign of disease deterioration in such cases. We call upon all the medical personnel to pay specific attention to original comorbidities, and patients with SSA needs early prevention of septic shock to improve overall outcome.
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